Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice
Document title: Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice
Journal: Annals of hepatology
Database: PERIÓDICA
System number: 000416605
ISSN: 1665-2681
Authors: 1
2
3
4
5
6
7
Institutions: 1Universidad Autónoma de Barcelona, Barcelona. España
2Hospital Universitario Infanta Sofía, Unidad de Gastroenterología, San Sebastián de los Reyes, Madrid. España
3Hospital Universitario La Princesa, Departamento de Gastroenterología, Madrid. España
4Hospital Universitario Infanta Leonor, Unidad de Gastroenterología, Madrid. España
5Hospital Carlos Haya, Departamento de Gastroenterología, Málaga. España
6Hospital Donostia, Departamento de Gastroenterología, San Sebastián, Guipúzcoa. España
7Hospital de Castellón, Departamento de Gastroenterología, Castellón. España
Year:
Season: Mar-Abr
Volumen: 12
Number: 2
Pages: 205-212
Country: México
Language: Inglés
Document type: Artículo
Approach: Experimental, caso clínico
English abstract This study aimed to evaluate the efficacy and safety of entecavir and/or tenofovir in compensated (CC) or decompensated (DC) hepatitis B cirrhotic patients in real-life clinical practice. Of the 48 patients, included between April 2007 and March 2010, 12 were DC. The mean age was 55 ± 12.2 years, 85.4% were Caucasians and 8 patients were HBeAg positive. Mean viral load was 5.2 ± 1.9 log10 UI/mL. HBV-DNA undetectability at 3, 6, 12 and 24 months were 53.3%, 78.3%, 83.7% and 97.1%, respectively, similar in CC and DC. At 6 and 12 months, ≥ 80% of CC achieved ALT normalization, while only 42.9% and 71.4% in DC. After a median follow-up of 27.1 (0.7-45.3) months, 43 patients were Child Pugh Turcotte (CPT) class A (n = 39 at entry). In DC, progressive improvement in the MELD scores was observed: 12.73 (SD 4.5), 10.4 (SD 3.6) and 8.2 (SD 2.6), at baseline, 12 and 24 months, respectively. During follow-up, 7 patients died, 4 received liver transplantation and 5 developed hepatocellular carcinoma. In three out of four DC who died due to hepatic causes, these events occurred between the first 0.7 and 6.7 months, and all were CPT class C. Cumulative survival in CC vs. DC at 12 and 24 months were 94.4% vs. 66.7%, and 88.2% vs. 57.1%, respectively (log rank p = 0.03). No severe adverse events associated with entecavir or tenofovir were reported. In conclusion, in compensated and decompensated cirrhotic patients, entecavir and tenofovir were effective and well tolerated
Disciplines: Medicina
Keyword: Gastroenterología,
Terapéutica y rehabilitación,
Tenofovir,
Hepatitis B,
Hepatitis crónica,
Cirrosis,
Función hepática,
Eficacia,
Seguridad
Keyword: Gastroenterology,
Therapeutics and rehabilitation,
Tenofovir,
Hepatitis B,
Chronic hepatitis,
Cirrhosis,
Hepatic function,
Efficacy,
Safety
Full text: Texto completo (Ver PDF)